S. Baum

发表

The saturated fat and dietary carbohydrate debate : are they ‘ ‘ one and the same ’ ’ relative to cardiovascular risk ?

W. Willett, A. Lichtenstein, P. Kris-Etherton, 2022 .

N. Desai, C. M. Carter, R. Wade, 2019 .

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified

N. Desai, C. M. Carter, R. Wade, 2019, Therapeutics and clinical risk management.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta‐Analysis

M. Gulati, M. Khan, E. Michos, 2021, Journal of the American Heart Association.

Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.

Deepak L. Bhatt, W. Boden, S. Fazio, 2020, Future cardiology.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

B. Neuschwander‐Tetri, C. Moylan, R. Taub, 2019, The Lancet.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

J. Tardif, E. Steinhagen-Thiessen, J. Witztum, 2020, The New England journal of medicine.

Fatty acids in cardiovascular health and disease: a comprehensive update.

W. Willett, A. Lichtenstein, P. Kris-Etherton, 2012, Journal of clinical lipidology.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

PCSK9 inhibitor valuation: A science‐based review of the two recent models

C. Cannon, S. Baum, 2018, Clinical cardiology.

Guidelines that are just for guidance

S. Baum, S. Sundaravel, Jonathan Nieves, 2018 .

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

D. Gaudet, J. Tardif, C. Ballantyne, 2022, European heart journal.

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

D. Gaudet, J. Witztum, E. Hurh, 2020, European heart journal.

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins

C. Ballantyne, J. Plutzky, H. Bays, 2021, American journal of preventive cardiology.

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

S. Harrison, M. Chakravarthy, Z. Younes, 2021, The American journal of gastroenterology.

US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry.

Emily C. O'Brien, J. Knowles, D. Rader, 2016, Journal of clinical lipidology.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data

S. Baum, Jonathan Nieves, A. Durairaj, 2017, Current Treatment Options in Cardiovascular Medicine.

Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.

P. Thuluvath, M. Kipnes, M. Abdelmalek, 2022, The lancet. Gastroenterology & hepatology.

CHARACTERISTICS OF PATIENTS APPROVED AND DENIED ACCESS TO PCSK9I THERAPY BY PAYERS

R. Wade, N. Yurgin, D. Harrison, 2017 .

Fatty Acids and Their Derivatives in Cardiovascular Disease: Arachidonic, Eicosapentaenoic, and Docosahexaenoic Acids and Their Byproducts, the Eicosanoids and Docosanoids

S. Baum, Aidan Hamm, 2012, Current Cardiovascular Risk Reports.

Evinacumab in Patients with Refractory Hypercholesterolemia.

D. Gaudet, R. Hamlin, R. Rosenson, 2020, The New England journal of medicine.

Cardiovascular disease prevention in the health economics era: Clinicians need more than just prescription pads

S. Baum, 2020, American journal of preventive cardiology.

Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation.

R. Shamburek, R. Goldberg, E. de Marchena, 2016, Journal of clinical lipidology.

A review of the evidence for alternative and complementary medical approaches in the prevention of atherosclerotic cardiovascular disease and diabetes

S. Baum, Jonathan Nieves, 2017, Cardiovascular endocrinology.

PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers

P. Jellinger, James A. Underberg, P. Toth, 2017, Clinical cardiology.

Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins

W. Sasiela, R. McQueen, K. Ray, 2022, American Journal of Cardiovascular Drugs.

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

Hong Wang, D. Gaudet, M. Sabatine, 2022, The New England journal of medicine.

Pitfalls of population-based preventive medicine.

S. Baum, 2013, JAMA.

MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study

R. Taub, J. Frias, N. Alkhouri, 2018 .

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.

Lawrence A Leiter, A. Goldberg, E. Stroes, 2019, JAMA.

Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).

P. Shah, C. Ballantyne, P. McCullough, 2018, The American journal of cardiology.

The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia.

G. Watts, E. Sijbrands, P. Mata, 2014, Journal of clinical lipidology.

Precision screening for familial hypercholesterolaemia: a machine learning study applied to electronic health encounter data.

N. Shah, J. Knowles, D. Rader, 2019, The Lancet. Digital health.

Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study.

T. Sampietro, C. Kurtz, B. Hohenstein, 2019, Journal of clinical lipidology.

Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.

Emily C. O'Brien, J. Knowles, D. Rader, 2017, Atherosclerosis.

Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease.

J. Knowles, C. Ballantyne, K. Myers, 2017, Circulation.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

S. Humphries, S. Yamashita, G. Watts, 2016, The lancet. Diabetes & endocrinology.

Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

Emily C. O'Brien, J. Knowles, D. Rader, 2016, Circulation. Cardiovascular genetics.

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes

D. Rader, S. Gidding, D. Staszak, 2019, Circulation. Cardiovascular quality and outcomes.

A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia

D. Gaudet, D. Rader, C. Ballantyne, 2021, Atherosclerosis.

Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology

M. Gulati, K. Ferdinand, Tamar S. Polonsky, 2022, American journal of preventive cardiology.

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives.

Deepak L. Bhatt, A. Khera, C. Ballantyne, 2019, Journal of the American College of Cardiology.

Rethinking our Guideline System: Returning to Evidence Based Medicine as it was Originally Intended

S. Baum, 2016 .

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Saptarsi M. Haldar, S. Melquist, G. Watts, 2022, Nature Medicine.

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

Saptarsi M. Haldar, S. Melquist, Hong Wang, 2022, Nature Medicine.

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

D. Gaudet, D. Rader, C. Ballantyne, 2023, Nature Medicine.

Rounding the corner on residual risk: Implications of REDUCE‐IT for omega‐3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease

K. Scholz, S. Baum, 2019, Clinical cardiology.

Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology

A. Khera, M. Gulati, N. Wong, 2020, American Journal of Preventive Cardiology.

The 2017 high blood pressure clinical practice guideline: The old and the new

J. Newman, S. Baum, A. Schwartzbard, 2018, Clinical cardiology.

Dissecting lipid and lipoprotein issues in women: an in utero-through-menopause journey

T. Dayspring, S. Baum, 2015 .

Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.

D. Gaudet, J. Tardif, C. Ballantyne, 2022, Journal of clinical lipidology.

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

M. Sabatine, James A. Underberg, M. Koren, 2016, Postgraduate medicine.

Statins and Diabetes.

K. Maki, M. Dicklin, S. Baum, 2016, Endocrinology and metabolism clinics of North America.

Statins and diabetes.

K. Maki, M. Dicklin, S. Baum, 2015, Cardiology clinics.

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data

R. Lipton, S. Silberstein, S. Marcus, 2020, Journal of primary care & community health.

Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2023, Journal of the American Heart Association.

From the "Ivory Tower" to the trenches: A practical approach to the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines.

S. Baum, 2014, Journal of clinical lipidology.

Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States

R. Wade, Kiran J. Philip, S. Baum, 2021, American journal of preventive cardiology.

Abstract 12169: LDL-C Levels and Treatment Patterns Among Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

J. Knowles, D. Rader, C. Ballantyne, 2015 .

The American Society for Preventive Cardiology: Our 30‐year legacy

L. Sperling, S. Baum, N. Wong, 2016, Clinical cardiology.

Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.

R. Santos, D. Blom, L. Hemphill, 2017, Journal of clinical lipidology.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

D. Ledbetter, J. Knowles, D. Rader, 2018, Journal of the American College of Cardiology.

ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol.

S. Baum, 2013, The American journal of cardiology.

EPA and DHA: distinct yet essential n-3 fatty acids.

S. Baum, 2012, Journal of clinical lipidology.

Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a)

G. Watts, Huei Wang, M. Koren, 2020, Circulation.

Infections and Cardiovascular Disease in Women

S. Baum, 2000 .

Abstract 19888: Improved Longitudinal Low Density Lipoprotein Cholesterol Goal Achievement Among Familial Hypercholesterolemia Patients in the CASCADE FH Patient Registry

Emily C. O'Brien, J. Knowles, D. Rader, 2017 .